IMPORTANCE: Patients with migraine often cycle through multiple nonspecific preventive medications due to poor tolerability and/or inadequate efficacy leading to low adherence and increased disease burden. OBJECTIVE: To compare the efficacy, tolerability, patient adherence, and patient satisfaction between erenumab and nonspecific oral migraine preventive medications (OMPMs) in patients with episodic migraine (EM) who had previously failed 1 or 2 preventive treatments. DESIGN, SETTING, AND PARTICIPANTS: The 12-month prospective, interventional, global, multicenter, active-controlled, randomized clinical trial comparing sustained benefit of 2 treatment paradigms (erenumab qm vs oral prophylactics) in adult episodic migraine patients (APPRAISE) trial was a 12-month open-label, multicenter, active-controlled, phase 4 randomized clinical trial conducted from May 15, 2019, to October 1, 2021. This pragmatic trial was conducted at 84 centers across 17 countries. Overall, participants 18 years or older with a 12-month or longer history of migraine, and 4 or more but fewer than 15 monthly migraine days (MMDs) were included. INTERVENTIONS: Patients were randomized (2:1) to receive erenumab or OMPMs. Dose adjustment was permitted (label dependent). MAIN OUTCOMES AND MEASURES: The primary end point was the proportion of patients completing 1 year of the initially assigned treatment and achieving a reduction of 50% or greater from baseline in MMDs at month 12. Secondary end points included the cumulative mean change from baseline in MMDs during the treatment period and the proportion of responders according to the Patients' Global Impression of Change (PGIC) scale at month 12 for patients taking the initially assigned treatment. RESULTS: A total of 866 patients were screened, of whom 245 failed the screening and 621 completed the screening and baseline period. Of the 621 randomized patients (mean [SD] age, 41.3 [11.2] years; 545 female [87.8%]; 413 [66.5%] in the erenumab group; 208 [33.5%] in the OMPM group), 523 (84.2%) completed the treatment phase, and 98 (15.8%) discontinued the study. At month 12, significantly more patients assigned to erenumab vs OMPM achieved the primary end point (232 of 413 [56.2%] vs 35 of 208 [16.8%]; odds ratio [OR], 6.48; 95% CI, 4.28-9.82; P <.001). Compared with OMPMs, treatment with erenumab showed higher responder rate (314 of 413 [76.0%] vs 39 of 208 [18.8%]; OR, 13.75; 95% CI, 9.08-20.83; P <.001) on the PGIC scale (≥5 at month 12). Significant reduction in cumulative average MMDs was reported with erenumab treatment vs OMPM treatment (-4.32 vs -2.65; treatment difference [SE]: -1.67 [0.35] days; P < .001). Substantially fewer patients in the erenumab arm compared with the OMPM arm switched medication (9 of 413 [2.2%] vs 72 of 208 [34.6%]) and discontinued treatment due to adverse events (12 of 408 [2.9%] vs 48 of 206 [23.3%]). No new safety signals were identified. CONCLUSIONS AND RELEVANCE: Results of this randomized clinical trial demonstrated that earlier use of erenumab in patients with EM who failed 1 or 2 previous preventive treatments provided greater and sustained efficacy, safety, and adherence than continuous OMPM. TRIAL REGISTRATION: ClinicalTrials.gov Identifier: NCT03927144.

Center for Interdisciplinary Research in Health Universidade Católica Portuguesa Lisboa Portugal

Department of Neurology Ghent University Hospital Ghent Belgium

Department of Neurology Military Institute of Medicine National Research Institute Warsaw Poland

Former employee of Novartis Pharma AG Basel Switzerland

Headache and Neurological Pain Research Group Vall d'Hebron Institute of Research Department of Medicine Universitat Autònoma de Barcelona Spain

Headache Center Dado Medical sro Prague Czech Republic

Headache Unit Neurology Department Hospital Universitari Vall d'Hebron Barcelona Spain

Hospital da Luz Headache Center Neurology Department Hospital da Luz Lisboa Portugal

Neurological Practice Dr Stude Bochum Germany

Novartis Pharma AG Basel Switzerland

Novartis Pharmaceuticals Corporation East Hanover New Jersey

Erratum v

JAMA Neurol. 2024 May 1;81(5):556. doi: 10.1001/jamaneurol.2024.1238. PubMed

Zobrazit více v PubMed

Hepp Z, Dodick DW, Varon SF, Gillard P, Hansen RN, Devine EB. Adherence to oral migraine-preventive medications among patients with chronic migraine. Cephalalgia. 2015;35(6):478-488. doi:10.1177/0333102414547138 PubMed DOI

Goadsby PJ, Reuter U, Hallström Y, et al. . A controlled trial of erenumab for episodic migraine. N Engl J Med. 2017;377(22):2123-2132. doi:10.1056/NEJMoa1705848 PubMed DOI

Tepper S, Ashina M, Reuter U, et al. . Safety and efficacy of erenumab for preventive treatment of chronic migraine: a randomised, double-blind, placebo-controlled phase 2 trial. Lancet Neurol. 2017;16(6):425-434. doi:10.1016/S1474-4422(17)30083-2 PubMed DOI

Stauffer VL, Dodick DW, Zhang Q, Carter JN, Ailani J, Conley RR. Evaluation of Galcanezumab for the Prevention of Episodic Migraine: the EVOLVE-1 randomized clinical trial. JAMA Neurol. 2018;75(9):1080-1088. doi:10.1001/jamaneurol.2018.1212 PubMed DOI PMC

Skljarevski V, Matharu M, Millen BA, Ossipov MH, Kim BK, Yang JY. Efficacy and safety of galcanezumab for the prevention of episodic migraine: results of the EVOLVE-2 Phase 3 randomized controlled clinical trial. Cephalalgia. 2018;38(8):1442-1454. doi:10.1177/0333102418779543 PubMed DOI

Detke HC, Goadsby PJ, Wang S, Friedman DI, Selzler KJ, Aurora SK. Galcanezumab in chronic migraine: the randomized, double-blind, placebo-controlled REGAIN study. Neurology. 2018;91(24):e2211-e2221. doi:10.1212/WNL.0000000000006640 PubMed DOI PMC

Dodick DW, Silberstein SD, Bigal ME, et al. . Effect of fremanezumab compared with placebo for prevention of episodic migraine: a randomized clinical trial. JAMA. 2018;319(19):1999-2008. doi:10.1001/jama.2018.4853 PubMed DOI PMC

Silberstein SD, Dodick DW, Bigal ME, et al. . Fremanezumab for the preventive treatment of chronic migraine. N Engl J Med. 2017;377(22):2113-2122. doi:10.1056/NEJMoa1709038 PubMed DOI

Ashina M, Saper J, Cady R, et al. . Eptinezumab in episodic migraine: a randomized, double-blind, placebo-controlled study (PROMISE-1). Cephalalgia. 2020;40(3):241-254. doi:10.1177/0333102420905132 PubMed DOI PMC

Lipton RB, Goadsby PJ, Smith J, et al. . Efficacy and safety of eptinezumab in patients with chronic migraine: PROMISE-2. Neurology. 2020;94(13):e1365-e1377. doi:10.1212/WNL.0000000000009169 PubMed DOI PMC

Sacco S, Amin FM, Ashina M, et al. . European Headache Federation guideline on the use of monoclonal antibodies targeting the calcitonin gene related peptide pathway for migraine prevention: 2022 update. J Headache Pain. 2022;23(1):67. doi:10.1186/s10194-022-01431-x PubMed DOI PMC

American Headache Society . The American Headache Society position statement on integrating new migraine treatments into clinical practice. Headache. 2019;59(1):1-18. doi:10.1111/head.13456 PubMed DOI

Italian Medicines Agency . Attivazione web e pubblicazione schede di monitoraggio—registro AIMOVIG. Accessed February 20, 2024. https://www.aifa.gov.it/en/-/attivazione-web-e-pubblicazione-schede-di-monitoraggio-registro-aimovig

National Institute for Health and Care Excellence . Erenumab for preventing migraine. Accessed February 20, 2024. https://www.nice.org.uk/guidance/ta682/chapter/1-Recommendations

DGN. DGN Guidelines home page. Accessed February 20, 2024. https://dgn.org/leitlinien/

Hepp Z, Bloudek LM, Varon SF. Systematic review of migraine prophylaxis adherence and persistence. J Manag Care Pharm. 2014;20(1):22-33. doi:10.18553/jmcp.2014.20.1.22 PubMed DOI PMC

Hepp Z, Dodick DW, Varon SF, et al. . Persistence and switching patterns of oral migraine prophylactic medications among patients with chronic migraine: a retrospective claims analysis. Cephalalgia. 2017;37(5):470-485. doi:10.1177/0333102416678382 PubMed DOI PMC

Ford JH, Schroeder K, Nyhuis AW, Foster SA, Aurora SK. Cycling through migraine preventive treatments: implications for all-cause total direct costs and disease-specific costs. J Manag Care Spec Pharm. 2019;25(1):46-59. doi:10.18553/jmcp.2018.18058 PubMed DOI PMC

Blumenfeld AM, Bloudek LM, Becker WJ, et al. . Patterns of use and reasons for discontinuation of prophylactic medications for episodic migraine and chronic migraine: results from the second international burden of migraine study (IBMS-II). Headache. 2013;53(4):644-655. doi:10.1111/head.12055 PubMed DOI

Kawata AK, Shah N, Poon JL, et al. . Understanding the migraine treatment landscape prior to the introduction of calcitonin gene-related peptide inhibitors: results from the Assessment of Tolerability and Effectiveness in Migraine Patients using Preventive Treatment (ATTAIN) study. Headache. 2021;61(3):438-454. doi:10.1111/head.14053 PubMed DOI PMC

Collaborators GBDN; GBD 2016 Neurology Collaborators . Global, regional, and national burden of neurological disorders, 1990-2016: a systematic analysis for the Global Burden of Disease Study 2016. Lancet Neurol. 2019;18(5):459-480. doi:10.1016/S1474-4422(18)30499-X PubMed DOI PMC

Steiner TJ, Stovner LJ, Jensen R, Uluduz D, Katsarava Z; Lifting The Burden: the Global Campaign against Headache . Migraine remains second among the world’s causes of disability, and first among young women: findings from GBD2019. J Headache Pain. 2020;21(1):137. doi:10.1186/s10194-020-01208-0 PubMed DOI PMC

Lipton RB, Bigal ME, Diamond M, Freitag F, Reed ML, Stewart WF; AMPP Advisory Group . Migraine prevalence, disease burden, and the need for preventive therapy. Neurology. 2007;68(5):343-349. doi:10.1212/01.wnl.0000252808.97649.21 PubMed DOI

Adams AM, Serrano D, Buse DC, et al. . The impact of chronic migraine: the Chronic Migraine Epidemiology and Outcomes (CaMEO) study methods and baseline results. Cephalalgia. 2015;35(7):563-578. doi:10.1177/0333102414552532 PubMed DOI PMC

Blumenfeld AM, Varon SF, Wilcox TK, et al. . Disability, HRQoL and resource use among chronic and episodic migraineurs: results from the International Burden of Migraine Study (IBMS). Cephalalgia. 2011;31(3):301-315. doi:10.1177/0333102410381145 PubMed DOI

Irimia P, Garrido-Cumbrera M, Santos-Lasaosa S, et al. . Impact of monthly headache days on anxiety, depression, and disability in migraine patients: results from the Spanish Atlas. Sci Rep. 2021;11(1):8286. doi:10.1038/s41598-021-87352-2 PubMed DOI PMC

Martelletti P, Schwedt TJ, Lanteri-Minet M, et al. . My Migraine Voice survey: a global study of disease burden among individuals with migraine for whom preventive treatments have failed. J Headache Pain. 2018;19(1):115. doi:10.1186/s10194-018-0946-z PubMed DOI PMC

Pozo-Rosich P, Lucas C, Watson DPB, et al. . Burden of migraine in patients with preventive treatment failure attending european headache specialist centers: real-world evidence from the BECOME study. Pain Ther. 2021;10(2):1691-1708. doi:10.1007/s40122-021-00331-3 PubMed DOI PMC

Ashina M, Goadsby PJ, Reuter U, et al. . Long-term efficacy and safety of erenumab in migraine prevention: results from a 5-year, open-label treatment phase of a randomized clinical trial. Eur J Neurol. 2021;28(5):1716-1725. doi:10.1111/ene.14715 PubMed DOI PMC

Dodick DW, Ashina M, Brandes JL, et al. . ARISE: a phase 3 randomized trial of erenumab for episodic migraine. Cephalalgia. 2018;38(6):1026-1037. doi:10.1177/0333102418759786 PubMed DOI

Reuter U, Goadsby PJ, Lanteri-Minet M, et al. . Efficacy and tolerability of erenumab in patients with episodic migraine in whom 2-to-4 previous preventive treatments were unsuccessful: a randomised, double-blind, placebo-controlled, phase 3b study. Lancet. 2018;392(10161):2280-2287. doi:10.1016/S0140-6736(18)32534-0 PubMed DOI

Barbanti P, Aurilia C, Egeo G, et al. . Erenumab in the prevention of high-frequency episodic and chronic migraine: Erenumab in Real Life in Italy (EARLY), the first Italian multicenter, prospective real-life study. Headache. 2021;61(2):363-372. doi:10.1111/head.14032 PubMed DOI

Torres-Ferrús M, Gallardo VJ, Alpuente A, Caronna E, Gine-Cipres E, Pozo-Rosich P. The impact of anti-CGRP monoclonal antibodies in resistant migraine patients: a real-world evidence observational study. J Neurol. 2021;268(10):3789-3798. doi:10.1007/s00415-021-10523-8 PubMed DOI

Ornello R, Casalena A, Frattale I, et al. . Conversion from chronic to episodic migraine in patients treated with erenumab: real-life data from an Italian region. J Headache Pain. 2020;21(1):102. doi:10.1186/s10194-020-01171-w PubMed DOI PMC

Scheffler A, Messel O, Wurthmann S, et al. . Erenumab in highly therapy-refractory migraine patients: first German real-world evidence. J Headache Pain. 2020;21(1):84. doi:10.1186/s10194-020-01151-0 PubMed DOI PMC

Alex A, Vaughn C, Rayhill M. Safety and tolerability of 3 CGRP monoclonal antibodies in practice: a retrospective cohort study. Headache. 2020;60(10):2454-2462. doi:10.1111/head.13956 PubMed DOI

Reuter U, Ehrlich M, Gendolla A, et al. . Erenumab versus topiramate for the prevention of migraine - a randomised, double-blind, active-controlled phase 4 trial. Cephalalgia. 2022;42(2):108-118. doi:10.1177/03331024211053571 PubMed DOI PMC

Headache Classification Committee of the International Headache Society (IHS) The International Classification of Headache Disorders 3rd edition. Cephalalgia . 2018;38(1):1-211. doi:10.1177/0333102417738202 PubMed DOI

Fischer D, Stewart AL, Bloch DA, Lorig K, Laurent D, Holman H. Capturing the patient’s view of change as a clinical outcome measure. JAMA. 1999;282(12):1157-1162. doi:10.1001/jama.282.12.1157 PubMed DOI

Vo P, Gao W, Zichlin ML, et al. . Real-world healthcare resource utilization related to migraine treatment failure: a panel-based chart review in France, Germany, Italy, and Spain. J Med Econ. 2019;22(9):953-959. doi:10.1080/13696998.2019.1636051 PubMed DOI

Bloudek LM, Stokes M, Buse DC, et al. . Cost of healthcare for patients with migraine in 5 European countries: results from the International Burden of Migraine Study (IBMS). J Headache Pain. 2012;13(5):361-378. doi:10.1007/s10194-012-0460-7 PubMed DOI PMC

Negro A, Sciattella P, Rossi D, Guglielmetti M, Martelletti P, Mennini FS. Cost of chronic and episodic migraine patients in continuous treatment for 2 years in a tertiary level headache Centre. J Headache Pain. 2019;20(1):120. doi:10.1186/s10194-019-1068-y PubMed DOI PMC

Munakata J, Hazard E, Serrano D, et al. . Economic burden of transformed migraine: results from the American Migraine Prevalence and Prevention (AMPP) Study. Headache. 2009;49(4):498-508. doi:10.1111/j.1526-4610.2009.01369.x PubMed DOI

Linde M, Gustavsson A, Stovner LJ, et al. . The cost of headache disorders in Europe: the Eurolight project. Eur J Neurol. 2012;19(5):703-711. doi:10.1111/j.1468-1331.2011.03612.x PubMed DOI

Hong JB, Lange KS, Fitzek M, et al. . Impact of a reimbursement policy change on treatment with erenumab in migraine—a real-world experience from Germany. J Headache Pain. 2023;24(1):144. doi:10.1186/s10194-023-01682-2 PubMed DOI PMC

Seddik AH, Schiener C, Ostwald DA, Schramm S, Huels J, Katsarava Z. Social impact of prophylactic migraine treatments in Germany: a state-transition and open cohort approach. Value Health. 2021;24(10):1446-1453. doi:10.1016/j.jval.2021.04.1281 PubMed DOI

Siersbæk N, Kilsdal L, Jervelund C, Antic S, Bendtsen L. Real-world evidence on the economic implications of CGRP-mAbs as preventive treatment of migraine. BMC Neurol. 2023;23(1):254. doi:10.1186/s12883-023-03302-7 PubMed DOI PMC

Mercieca-Bebber R, King MT, Calvert MJ, Stockler MR, Friedlander M. The importance of patient-reported outcomes in clinical trials and strategies for future optimization. Patient Relat Outcome Meas. 2018;9:353-367. doi:10.2147/PROM.S156279 PubMed DOI PMC

Alpuente A, Gallardo VJ, Caronna E, Torres-Ferrus M, Pozo-Rosich P. In search of a gold standard patient-reported outcome measure to use in the evaluation and treatment-decision making in migraine prevention: a real-world evidence study. J Headache Pain. 2021;22(1):151. doi:10.1186/s10194-021-01366-9 PubMed DOI PMC

Colloca L. The placebo effect in pain therapies. Annu Rev Pharmacol Toxicol. 2019;59:191-211. doi:10.1146/annurev-pharmtox-010818-021542 PubMed DOI PMC

Tepper SJ, Cirillo J, Kim E, et al. . The temporal trend of placebo response in migraine prevention from 1990 to 2021: a systematic literature review and meta-analysis with regression. J Headache Pain. 2023;24(1):54. doi:10.1186/s10194-023-01587-0 PubMed DOI PMC

de Craen AJ, Tijssen JG, de Gans J, Kleijnen J. Placebo effect in the acute treatment of migraine: subcutaneous placebos are better than oral placebos. J Neurol. 2000;247(3):183-188. doi:10.1007/s004150050560 PubMed DOI

Enck P, Klosterhalfen S. Placebos and the Placebo Effect in Drug Trials. Handb Exp Pharmacol. 2019;260:399-431. doi:10.1007/164_2019_269 PubMed DOI

Efficacy and Safety of Erenumab for Nonopioid Medication Overuse Headache in Chronic Migraine: A Phase 4, Randomized, Placebo-Controlled Trial

Zobrazit více v PubMed

ClinicalTrials.gov
NCT03927144